67 158

성장인자수용체-2 양성 유방암 조직에서 표적치료 전후의 성장인자수용체군 발현양상

Other Titles
 Expression of growth factor receptor family before and after targeted therapy in human epidermal growth factor receptor-2 positive breast cancer tissues 
Authors
 박세호  ;  고영신  ;  구자승  ;  손주혁  ;  김승일  ;  박병우 
Citation
 Korean Journal of Clinical Oncology (대한임상종양학회지), Vol.11(1) : 12-19, 2015 
Journal Title
 Korean Journal of Clinical Oncology  (대한임상종양학회지) 
ISSN
 1738-8082 
Issue Date
2015
Abstract
Purpose: This study aimed to compare expression of human epidermal growth factor receptor (HER) family and insulin-like growth factor-1 receptor (IGF-1R) before and after targeted therapy in HER-2 positive breast cancers. Methods: Epidermal growth factor receptor (EGFR), HER-3, HER-4, and IGF-1R were immunohistochemically determined using pairwise archives tumor blocks of 28 patients received chemotherapy and HER-2 directed therapy between January 2007 and December 2011. Of them, 5 good responders achieved a pathologic complete response after neoadjuvant therapy and 23 poor responders experienced disease progression or metastasis even HER-2 targeted therapy. Expression of biomarkers was compared using chi-square test. Results: Stage II, III, and IV was 14 (50.0%), 11 (39.3%), and 3 (10.7%) patients, respectively. Hormone receptors-positive tumors were 15 (53.6%) patients and 9 (32.1%) patients received tyrosine kinase inhibitors with or without trastuzumab. Positive expression of initial EGFR, HER-3, HER-4, and IGF-1R was determined in 15 (53.6%), 11 (39.3%), 22 (78.6%), and 14 (50.0%) patients, respectively. Although there was no statistical significance, good responders showed a higher proportion of positive HER-3 expression. Among 23 poor responders, growth factor receptors family expression showed a trend of concordant results, however, unpredictively certain patients demonstrated discordant results between before and after targeted therapy. Conclusion: Unpredicted correlation of growth factor receptors family expression suggested that complex and personalized resistance mechanisms may be involved to HER-2 directed therapy. However, HER-3 expression might be associated with responsiveness to HER-2 targeted therapy. It would be important to develop diagnostic and therapeutic strategies for overcoming resistance to HER-2 targeted therapy.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/140547
Files in This Item:
T201502228.pdf Download
DOI
10.14216/kjco.15003
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실)
Yonsei Authors
구자승(Koo, Ja Seung) ORCID logo https://orcid.org/0000-0003-4546-4709
김승일(Kim, Seung Il)
박병우(Park, Byeong Woo)
박세호(Park, Se Ho)
손주혁(Sohn, Joo Hyuk)
Export
RIS (EndNote)
XLS (Excel)
XML
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse